This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: inclisiran

New opportunity for cholesterol lowering: inclisiran

September 2021 Br J Cardiol 2021;28(suppl 2):S13–S18 doi:10.5837/bjc.2021.s08

New opportunity for cholesterol lowering: inclisiran

Julia Brandts, Kausik K Ray

Abstract

Introduction The role of low-density lipoproteins (LDLs) in the development of atherosclerotic disease is proven.1 Several approaches to lowering LDL-cholesterol (LDL-C) exist, including blocking dietary cholesterol absorption (ezetimibe) or restricting cholesterol synthesis (statins and bempedoic acid). All three of these medication types result in a decreased intracellular cholesterol concentration, which, in turn, activates LDL-receptor expression. As we have seen in the previous article (pages S7–S12), increasing the quantity or durability of LDL-receptors on the hepatocyte surface enhances LDL-C clearance from the bloodstream. Guidelin

| Full text
Inclisiran: testing a population health management methodology to implement a novel lipid treatment

September 2021 Br J Cardiol 2021;28(suppl 2):S19–S22 doi:10.5837/bjc.2021.s09

Inclisiran: testing a population health management methodology to implement a novel lipid treatment

Samantha Dixon, Linda Rootkin, Tracey Vell

Abstract

Introduction Cardiovascular disease (CVD) affects around seven million people in the UK. It is a significant cause of disability and is responsible for one in four premature deaths – accounting for the largest gap in health life-expectancy. It is also an area where there are significant health inequalities, with those in the most deprived 10% of the population almost twice as likely to die as a result of CVD, than those in the least deprived 10% of the population.1 Box 1. Five major practical changes to the NHS service model2 We will boost ‘out-of-hospital’ care, and finally dissolve the historic divide between primary and commu

| Full text

December 2020

Inclisiran data shows good results LDL-C reduction across race and gender

BJC Staff

Abstract

Data presented at the recent American Heart Association Scientific Sessions 2020, showed pooled results from three ORION phase III trials in more than 3,600 patients with atherosclerotic cardiovascular disease (or heterozygous familial hypercholesterolemia (HeFH), who were given inclisiran at months 1, 3 and then every 6 months up to month 17. Results of the first analysis showed LDL-C reductions of approximately 51% from baseline for both women and men at 17 months. A second analysis demonstrated treatment with inclisiran lowered LDL-C similarly by approximately 51% across three age groups (<65, ≥65 to <75, and ≥75 years old). In b

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now